EpiPen maker under investigation for antitrust violations in New York
(By Ike Swetlitz for STAT) New York Attorney General Eric T. Schneiderman is investigating Mylan Pharmaceuticals for potential antitrust violations involving
Read More
Part D/Prescription Drugs
Gene therapy for sickle cell moves closer as scientists clear unexpected obstacle
(By Sharon Begley for STAT) Researchers have cleared the last scientific hurdle to a clinical trial of gene therapy1 to cure sickle
Read MoreSaline Nose Spray Might Help Tame Severe Nosebleeds
(By Nancy Shute for NPR) Saline nose spray is becoming increasingly popular as a treatment for allergies and sinus problems.
Read MoreThe drug pricing crusader at the center of one of the nastiest fights of the election season
(By Rebecca Robbins for STAT) LOS ANGELES — There’s nobody the drug companies are spending more to fight than Michael
Read MoreHHS accelerates development of mRNA-based Zika vaccine
(Source – www.hhs.gov) The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response
Read MoreAllergan CEO promises to limit price hikes on drugs in a bid to rebuild the ‘social contract’
(By Ed Silverman for STAT) Seeking to deflect harsh criticism of the pharmaceutical industry, one chief executive officer — Allergan’s
Read MoreThe secretive system for vetting cancer drug use needs an urgent overhaul
(By Ed Silverman for STAT) In the complicated world of medicine and money, the federal government relies on a handful
Read MoreEpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog
(By Sydney Lupkin for Kaiser Health News) Consumers and Congress members pushing for cheaper alternatives to the EpiPen and other
Read MoreHidden network of kratom devotees tries to keep the supplement safe — and legal
(By Eric Boodman for STAT) When money is scarce, Margo Burton and her husband will go without cigarettes. Sometimes her
Read MoreAnyone see the rebates? Lawmakers accuse Mylan of underpaying Medicaid for EpiPen
(By Ed Silverman for STAT) Did Mylan Pharmaceuticals misclassify EpiPen to avoid paying higher Medicaid rebates? Continue reading article here…..
Read More